

# Massimo Valerio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10991134/publications.pdf>

Version: 2024-02-01

86  
papers

3,806  
citations

201674

27  
h-index

138484

58  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4425  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. <i>European Urology</i> , 2022, 81, 193-203.	1.9	30
2	An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 350-357.	0.4	13
3	An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?. <i>European Urology</i> , 2022, 81, 5-33.	1.9	66
4	Features and management of men with pN1 cMO prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. <i>Current Opinion in Urology</i> , 2022, 32, 69-84.	1.8	6
5	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. <i>European Urology</i> , 2022, 81, 407-413.	1.9	41
6	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210819.	3.2	12
7	Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer. <i>Cancers</i> , 2022, 14, 1135.	3.7	5
8	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer – Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	3.7	2
9	Re: Multiparametric Ultrasound Versus Multiparametric MRI To Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study. <i>European Urology</i> , 2022, , .	1.9	0
10	Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. <i>European Urology Focus</i> , 2022, 8, 1622-1626.	3.1	4
11	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021, 4, 745-754.	5.4	17
12	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	3.1	19
13	3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 349-357.	3.9	35
14	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 301-308.	3.1	11
15	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 567-574.	3.9	28
16	Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study. <i>Investigative and Clinical Urology</i> , 2021, 62, 416.	2.0	3
17	Radical Prostatectomy: Sequelae in the Course of Time. <i>Frontiers in Surgery</i> , 2021, 8, 684088.	1.4	4
18	The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 297.e9-297.e16.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Focal Therapy for Prostate Cancer: Complications and Their Treatment. <i>Frontiers in Surgery</i> , 2021, 8, 696242.	1.4	13
20	Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. <i>Frontiers in Surgery</i> , 2021, 8, 691473.	1.4	5
21	Intramuscular Immunization Induces Antigen-specific Antibodies in Urine. <i>European Urology Focus</i> , 2020, 6, 280-283.	3.1	0
22	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>Eur Urol</i> 2019;76:27-30. <i>European Urology</i> , 2020, 77, e103-e104.	1.9	0
23	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2020, 77, 733-741.	1.9	85
24	Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.02.009">https://doi.org/10.1016/j.eururo.2020.02.009</a> . <i>European Urology</i> , 2020, 78, e67-e68.	1.9	0
25	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. <i>European Urology Focus</i> , 2020, 7, 1247-1253.	3.1	7
26	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology Oncology</i> , 2020, 3, 739-747.	5.4	31
27	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. <i>European Urology Oncology</i> , 2020, 3, 565-581.	5.4	46
28	The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 846.e1-846.e7.	1.6	9
29	Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2-year results of the MT-02-study. <i>World Journal of Urology</i> , 2020, 38, 3235-3244.	2.2	30
30	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	1.9	55
31	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 747-747.	0.4	0
32	Imaging modalities in synchronous oligometastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2573-2583.	2.2	16
33	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. <i>World Journal of Urology</i> , 2019, 37, 243-251.	2.2	37
34	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
35	Hereditary prostate cancer - Primetime for genetic testing?. <i>Cancer Treatment Reviews</i> , 2019, 81, 101927.	7.7	20
36	Salvage Local Treatments After Focal Therapy for Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 526-538.	5.4	31

#	ARTICLE	IF	CITATIONS
37	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 284-303.	1.9	153
38	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. <i>Frontiers in Immunology</i> , 2019, 10, 622.	4.8	55
39	Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?. <i>Cancer Treatment Reviews</i> , 2019, 75, 20-26.	7.7	23
40	Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?. <i>World Journal of Urology</i> , 2019, 37, 277-287.	2.2	51
41	Reduction and follow-up of hospital discharge letter delay using Little’s law. <i>International Journal for Quality in Health Care</i> , 2019, 31, 787-792.	1.8	3
42	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>European Urology</i> , 2019, 76, 98-105.	1.9	96
43	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 320-334.	0.8	28
44	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. <i>European Urology</i> , 2019, 75, 506-514.	1.9	188
45	Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. <i>BJU International</i> , 2019, 123, 1061-1069.	2.5	47
46	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 76, 493-504.	1.9	111
47	Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. <i>Eur Urol</i> 2018;74:84–91. <i>European Urology</i> , 2019, 75, e21-e22.	1.9	2
48	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , 2019, 5, 171-178.	3.1	50
49	Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology. <i>World Journal of Urology</i> , 2018, 36, 1489-1494.	2.2	1
50	Re: Effect of Prior Focal Therapy on Perioperative, Oncologic and Functional Outcomes of Salvage Robotic Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 199, 1634-1635.	0.4	0
51	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 529.e11-529.e22.	1.6	31
52	How can we expand active surveillance criteria in patients with low and intermediate risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	2.5	27
53	New technologies and techniques for prostate cancer focal therapy. <i>Minerva Urology and Nephrology</i> , 2018, 70, 252-263.	2.5	18
54	Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 150.e1-150.e7.	1.6	37

#	ARTICLE	IF	CITATIONS
55	An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements. <i>APL Bioengineering</i> , 2017, 1, 016101.	6.2	17
56	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle Invasive Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 717-725.	7.0	24
57	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. <i>European Urology</i> , 2017, 71, 17-34.	1.9	232
58	Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 647-654.	0.4	66
59	Focal therapy as primary treatment for localized prostate cancer: definition, needs and future. <i>Future Oncology</i> , 2017, 13, 727-741.	2.4	28
60	The role of renal biopsy in small renal masses. <i>Canadian Urological Association Journal</i> , 2016, 10, 28.	0.6	19
61	Transperineal template prostate mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer. <i>BJU International</i> , 2016, 118, 384-390.	2.5	23
62	Addressing overtreatment following the diagnosis of localized prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 373-374.	2.4	2
63	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. <i>European Urology Focus</i> , 2016, 2, 514-521.	3.1	11
64	The challenging landscape of medical device approval in localized prostate cancer. <i>Nature Reviews Urology</i> , 2016, 13, 91-98.	3.8	5
65	Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. <i>Insights Into Imaging</i> , 2016, 7, 205-214.	3.4	45
66	Methodological considerations in assessing the utility of imaging in early prostate cancer. <i>Current Opinion in Urology</i> , 2015, 25, 536-542.	1.8	8
67	Identifying the Index Lesion with Template Prostate Mapping Biopsies. <i>Journal of Urology</i> , 2015, 193, 1185-1190.	0.4	16
68	Technological aspects of delivering cryotherapy for prostate cancer. <i>Expert Review of Medical Devices</i> , 2015, 12, 183-190.	2.8	9
69	Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 424.e9-424.e16.	1.6	44
70	Focal Therapy of Prostate Cancer Using Irreversible Electroporation. <i>Techniques in Vascular and Interventional Radiology</i> , 2015, 18, 147-152.	1.0	13
71	Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging- Ultrasound Fusion Targeted Biopsy: A Systematic Review. <i>European Urology</i> , 2015, 68, 8-19.	1.9	381
72	Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study. <i>Canadian Urological Association Journal</i> , 2014, 8, 600.	0.6	8

#	ARTICLE	IF	CITATIONS
73	Health technology assessment in evolution – focal therapy in localised prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 1359-1367.	2.4	7
74	Focal Therapy Will Become a Standard Option for Selected Men With Localized Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 3680-3681.	1.6	15
75	The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. European Urology, 2014, 66, 732-751.	1.9	298
76	Re: Jarow et al.: Drug and Device Development for Localized Prostate Cancer: Report of a Food and Drug Administration/American Urological Association Public Workshop (Urology 2014;83:975-979). Urology, 2014, 84, 732-733.	1.0	3
77	A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemporary Clinical Trials, 2014, 39, 57-65.	1.8	53
78	Re: Tumor Target Volume for Focal Therapy of Prostate Cancer – Does Multiparametric Magnetic Resonance Imaging Allow for a Reliable Estimation?. Journal of Urology, 2014, 192, 1297-1298.	0.4	3
79	Defining the level of evidence for technology adoption in the localized prostate cancer pathway. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 924-930.	1.6	7
80	Enhanced Recovery After Surgery: Are We Ready, and Can We Afford Not to Implement These Pathways for Patients Undergoing Radical Cystectomy?. European Urology, 2014, 65, 263-266.	1.9	102
81	Experimental evaluation of an electromechanical artificial urinary sphincter in an animal model. BJU International, 2013, 112, E337-E343.	2.5	19
82	Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations. Clinical Nutrition, 2013, 32, 879-887.	5.0	572
83	Are Patients at Nutritional Risk More Prone to Complications after Major Urological Surgery?. Journal of Urology, 2013, 190, 2126-2132.	0.4	34
84	Percutaneous drainage and sclerotherapy as definitive treatment of renal lymphangiomatosis. Canadian Urological Association Journal, 2012, 6, E3-7.	0.6	7
85	Metastatic primary adenocarcinoma of the bladder in a twenty-five years old woman. Rare Tumors, 2011, 3, 28-29.	0.6	6
86	The SAFE Pilot Trial – Salvage Focal Irreversible Electroporation – For Recurrent Localized Prostate Cancer: Rationale and Study Protocol. Frontiers in Surgery, 0, 9, .	1.4	5